|
1
|
American Diabetes Association. 11.
microvascular complications and foot care: Standards of medical
care in diabetes-2021. Diabetes Care. 44 (Suppl 1):S151–S167.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cheung N, Mitchell P and Wong TY: Diabetic
retinopathy. Lancet. 376:124–136. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang Z, Tang J, Jin E, Zhong Y, Zhang L,
Han X, Liu J, Cheng Y, Hou J, Shi X, et al: Serum untargeted
metabolomics reveal potential biomarkers of progression of diabetic
retinopathy in asians. Front Mol Biosci. 9(871291)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Peddada KV, Brown A, Verma V and Nebbioso
M: Therapeutic potential of curcumin in major retinal pathologies.
Int Ophthalmol. 39:725–734. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Semeraro F, Morescalchi F, Cancarini A,
Russo A, Rezzola S and Costagliola C: Diabetic retinopathy, a
vascular and inflammatory disease: Therapeutic implications.
Diabetes Metab. 45:517–527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Antonetti DA, Klein R and Gardner TW:
Diabetic retinopathy. N Engl J Med. 366:1227–1239. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stitt AW, Curtis TM, Chen M, Medina RJ,
McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R and
Lois N: The progress in understanding and treatment of diabetic
retinopathy. Prog Retin Eye Res. 51:156–186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Boyer DS, Hopkins JJ, Sorof J and Ehrlich
JS: Anti-vascular endothelial growth factor therapy for diabetic
macular edema. Ther Adv Endocrinol Metab. 4:151–169.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lin TW, Chien Y, Lin YY, Wang ML,
Yarmishyn AA, Yang YP, Hwang DK, Peng CH, Hsu CC, Chen SJ and Chien
KH: Establishing liposome-immobilized dexamethasone-releasing PDMS
membrane for the cultivation of retinal pigment epithelial cells
and suppression of neovascularization. Int J Mol Sci.
20(241)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Choi AY, Cho H and Kim YC: Effect of two
different doses of intravitreal bevacizumab with temporal
retina-sparing laser photocoagulation for retinopathy of
prematurity. Int J Ophthalmol. 11:166–169. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Heiduschka P, Plagemann T, Li L, Alex AF
and Eter N: Different effects of various anti-angiogenic treatments
in an experimental mouse model of retinopathy of prematurity. Clin
Exp Ophthalmol. 47:79–87. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sophie R, Lu N and Campochiaro PA:
Predictors of functional and anatomic outcomes in patients with
diabetic macular edema treated with ranibizumab. Ophthalmology.
122:1395–1401. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang Q, Navitskaya S, Chakravarthy H,
Huang C, Kady N, Lydic TA, Chen YE, Yin KJ, Powell FL, Martin PM,
et al: Dual anti-inflammatory and anti-angiogenic action of miR-15a
in diabetic retinopathy. EBioMedicine. 11:138–150. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Temelkova-Kurktschiev T, Henkel E, Koehler
C, Karrei K and Hanefeld M: Subclinical inflammation in newly
detected type II diabetes and impaired glucose tolerance.
Diabetologia. 45(151)2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pradhan AD, Manson JE, Rifai N, Buring JE
and Ridker PM: C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus. JAMA. 286:327–334.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hillier RJ, Ojaimi E, Wong DT, Mak MYK,
Berger AR, Kohly RP, Kertes PJ, Forooghian F, Boyd SR, Eng K, et
al: Aqueous humor cytokine levels and anatomic response to
intravitreal ranibizumab in diabetic macular edema. JAMA
Ophthalmol. 136:382–388. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pessoa B, Heitor J, Coelho C, Leander M,
Menéres P, Figueira J, Meireles A and Beirão M: Systemic and
vitreous biomarkers-new insights in diabetic retinopathy. Graefes
Arch Clin Exp Ophthalmol. 260:2449–2460. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Muni RH, Kohly RP, Lee EQ, Manson JE,
Semba RD and Schaumberg DA: Prospective study of inflammatory
biomarkers and risk of diabetic retinopathy in the diabetes control
and complications trial. JAMA Ophthalmol. 131:514–521.
2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li J, Zhao T and Sun Y: Interleukin-17A in
diabetic retinopathy: The crosstalk of inflammation and
angiogenesis. Biochem Pharmacol. 225(116311)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qiu AW, Bian Z, Mao PA and Liu QH: IL-17A
exacerbates diabetic retinopathy by impairing Müller cell function
via Act1 signaling. Exp Mol Med. 48(e280)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Qiu AW, Liu QH and Wang JL: Blocking
IL-17A alleviates diabetic retinopathy in rodents. Cell Physiol
Biochem. 41:960–972. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jonas JB, Tao Y, Neumaier M and Findeisen
P: Monocyte chemoattractant protein 1, intercellular adhesion
molecule 1, and vascular cell adhesion molecule 1 in exudative
age-related macular degeneration. Arch Ophthalmol. 128:1281–1286.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Miyamoto K, Khosrof S, Bursell SE,
Moromizato Y, Aiello LP, Ogura Y and Adamis AP: Vascular
endothelial growth factor (VEGF)-induced retinal vascular
permeability is mediated by intercellular adhesion molecule-1
(ICAM-1). Am J Pathol. 156:1733–1739. 2000.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Haneda S and Yamashita H: International
clinical diabetic retinopathy disease severity scale. Nihon Rinsho.
68 (Suppl 9):S228–S235. 2010.PubMed/NCBI(In Japanese).
|
|
25
|
Bai J, Yang F, Wang R and Yan Q: Ghrelin
ameliorates diabetic retinal injury: Potential therapeutic avenues
for diabetic retinopathy. Oxid Med Cell Longev.
2021(8043299)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gaffen SL: Recent advances in the IL-17
cytokine family. Curr Opin Immunol. 23:613–619. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhong H and Sun X: Contribution of
interleukin-17A to retinal degenerative diseases. Front Immunol.
13(847937)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yan A, Zhang Y, Wang X, Cui Y and Tan W:
Interleukin 35 regulates interleukin 17 expression and T helper 17
in patients with proliferative diabetic retinopathy. Bioengineered.
13:13293–13299. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Marwaha AK, Crome SQ, Panagiotopoulos C,
Berg KB, Qin H, Ouyang Q, Xu L, Priatel JJ, Levings MK and Tan R:
Cutting edge: Increased IL-17-secreting T cells in children with
new-onset type 1 diabetes. J Immunol. 185:3814–3818.
2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Setiadi AF, Abbas AR, Jeet S, Wong K,
Bischof A, Peng I, Lee J, Bremer M, Eggers EL, DeVoss J, et al:
IL-17A is associated with the breakdown of the blood-brain barrier
in relapsing-remitting multiple sclerosis. J Neuroimmunol.
332:147–154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Elahi R, Nazari M, Mohammadi V,
Esmaeilzadeh K and Esmaeilzadeh A: IL-17 in type II diabetes
mellitus (T2DM) immunopathogenesis and complications; molecular
approaches. Mol Immunol. 171:66–76. 2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zapadka TE, Lindstrom SI, Taylor BE, Lee
CA, Tang J, Taylor ZRR, Howell SJ and Taylor PR: RORγt
Inhibitor-SR1001 halts retinal inflammation, capillary
degeneration, and the progression of diabetic retinopathy. Int J
Mol Sci. 21(3547)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bharadwaj AS, Schewitz-Bowers LP, Wei L,
Lee RW and Smith JR: Intercellular adhesion molecule 1 mediates
migration of Th1 and Th17 cells across human retinal vascular
endothelium. Invest Ophthalmol Vis Sci. 54:6917–6925.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ding Y, Yang C, Zhou Z, Peng Y, Chen J,
Pan S, Xu H, Cai Y, Ou K, Xie W and Wang H: Clinical significance
of soluble adhesion molecules in anti-NMDAR encephalitis patients.
Ann Clin Transl Neurol. 6:945–953. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Nowak M, Wielkoszyński T, Marek B,
Kos-Kudła B, Swietochowska E, Siemińska L, Kajdaniuk D,
Głogowska-Szelag J and Nowak K: Blood serum levels of vascular cell
adhesion molecule (sVCAM-1), intercellular adhesion molecule
(sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in
diabetic retinopathy. Clin Exp Med. 8:159–164. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Blum A, Pastukh N, Socea D and Jabaly H:
Levels of adhesion molecules in peripheral blood correlat with
stages of diabetic retinopathy and may serve as bio markers for
microvascular complications. Cytokine. 106:76–79. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yao Y, Du J, Li R, Zhao L, Luo N, Zhai JY
and Long L: Association between ICAM-1 level and diabetic
retinopathy: A review and meta-analysis. Postgrad Med J.
95:162–168. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Baron VT, Pio R, Jia Z and Mercola D:
Early growth response 3 regulates genes of inflammation and
directly activates IL6 and IL8 expression in prostate cancer. Br J
Cancer. 112:755–764. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME,
Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia
JL and Melero I: Interleukin-8 in cancer pathogenesis, treatment
and follow-up. Cancer Treat Rev. 60:24–31. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Owen LA and Hartnett ME: Soluble mediators
of diabetic macular edema: The diagnostic role of aqueous VEGF and
cytokine levels in diabetic macular edema. Curr Diab Rep.
13:476–480. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lee WJ, Kang MH, Seong M and Cho HY:
Comparison of aqueous concentrations of angiogenic and inflammatory
cytokines in diabetic macular oedema and macular oedema due to
branch retinal vein occlusion. Br J Ophthalmol. 96:1426–1430.
2012.PubMed/NCBI View Article : Google Scholar
|
